Dilemmasituation: Orale Antikoagulation bei Dialysepatienten mit Vorhofflimmern

Für Patienten mit nicht valvulärem Vorhofflimmern (nvVHF) ohne fortgeschrittene chronische Nierenerkrankung ist die Thromboembolieprophylaxe mittels oraler Antikoagulation evidenzbasiert empfohlen. Aber wie sieht es für Patienten mit nvVHF im chronischen Hämodialyseprogramm aus? Die folgende Übersicht geht auf praxisrelevante Fragen an dieser wichtigen kardio-nephrologischen Schnittstelle ein.

Abstract

In patients with intact kidney function and in patients with mild to moderate chronic kidney disease (CKD), strong evidence suggests the use of non-vitamin K dependent oral anticoagulants (NOAC) for preventing ischemic strokes and systemic thromboembolic events in patients with non-valvular atrial fibrillation (nvAF) and elevated thromboembolic risk. In contrast, less evidence is available on the risk-benefit ratio of oral anticoagulation (OAC) in patients with nvAF and severe CKD, particularly in dialysis patients. No large randomised study has tested whether OAC will reduce the risk of thromboembolic events in nvAF without prohibitively high bleeding risk, and whether NOACs or vitamin K antagonists are the superior strategy for OAC. Considering absence of strong evidence, the authors suggest that in dialysis patients with nvAF, in whom the treatment team sees the clear need to prevent thromboembolic events, the use of NOACs or left atrial appendage occlusion should be preferred over treatment with vitamin K antagonists. Any OAC treatment for dialysis patients with nvAF is not in-label in most European countries.

Schlüsselwörter

orale Antikoagulation - Dialyse - Vorhofflimmern

Key words

oral anticoagulation - dialysis - non-valvular atrial fibrillation

Publication History

Article published online:
24 August 2020

• Literatur

• 1 Pokorney SD, Black-Maier E, Hellkamp AS. et al. Oral anticoagulation and cardiovascular outcomes in patients with atrial fibrillation and end-stage renal disease. J Am Coll Cardiol 2020; 75: 1299-1308
• 2 Heine GH, Brandenburg V, Schirmer SH. Oral anticoagulation in chronic kidney disease and atrial fibrillation. Dtsch Arztebl Int 2018; 115: 287-294
• 3 January CT, Wann LS, Calkins H. et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 2019; 140: e125-e151
• 4 Siontis KC, Zhang X, Eckard A. et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 2018; 138: 1519-1529
• 5 Kuno T, Takagi H, Ando T. et al. Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis. J Am Coll Cardiol 2020; 75: 273-285
• 6 De Vriese AS, Caluwé R, Pyfferoen L. et al. Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study. J Am Soc Nephrol 2020; 31: 186-196
• 7 Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. N Engl J Med 2018; 378: 1704-1714